Relapse/progression-free survival
| Variables . | EUROCORD (N = 496) . | JSTCT (N = 1150) . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Year of transplant, continuous variable | 0.99 | (0.95-1.03) | .542 | 0.96 | (0.95-0.98) | <.001 |
| Age∗ (<50 or ≥50) | ||||||
| 18-49 | 1.00 | Reference | 1.00 | Reference | ||
| 50-70 | 1.06 | (0.82-1.37) | .648 | 1.41 | (1.21-1.65) | <.001 |
| rDRI | ||||||
| Low | 1.00 | Reference | 1.00 | Reference | ||
| Intermediate | 1.18 | (0.91-1.55) | .218 | 1.46 | (1.06-2.02) | .022 |
| High or very high | 1.89 | (1.34-2.66) | <.001 | 2.35 | (1.71-3.23) | <.001 |
| Conditioning | ||||||
| TBI-RIC | 1.00 | Reference | 1.00 | Reference | ||
| TBI-MAC | 0.97 | (0.61-1.55) | .909 | 0.94 | (0.77-1.14) | .514 |
| Non–TBI-RIC | 1.84 | (1.33-2.53) | <.001 | 1.74 | (1.43-2.12) | <.001 |
| Non–TBI-MAC | 1.73 | (1.14-2.61) | .010 | 1.36 | (1.02-1.82) | .037 |
| GVHD prophylaxis | ||||||
| CI + MMF | 1.00 | Reference | 1.00 | Reference | ||
| CI + MTX | NA | NA | NA | 1.47 | (1.22-1.79) | <.001 |
| CI + steroid | 0.86 | (0.56-1.31) | .496 | NA | NA | NA |
| Others | 1.19 | (0.84-1.69) | .318 | 1.70 | (1.38-2.10) | <.001 |
| TNCs at collection per recipient weight (×107/kg)† | ||||||
| -First quartile | 1.00 | Reference | 1.00 | Reference | ||
| First-second quartile | 0.67 | (0.47-0.96) | .028 | 0.93 | (0.75-1.14) | .465 |
| Second-third quartile | 0.84 | (0.59-1.18) | .314 | 0.91 | (0.74-1.12) | .358 |
| Third quartile - | 0.88 | (0.61-1.26) | .482 | 0.98 | (0.80-1.21) | .874 |
| Number of HLA-MM | ||||||
| 0-1 | 1.00 | Reference | 1.00 | Reference | ||
| 2- | 1.36 | (1.03-1.81) | .030 | 1.17 | (0.96-1.42) | .119 |
| Variables . | EUROCORD (N = 496) . | JSTCT (N = 1150) . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Year of transplant, continuous variable | 0.99 | (0.95-1.03) | .542 | 0.96 | (0.95-0.98) | <.001 |
| Age∗ (<50 or ≥50) | ||||||
| 18-49 | 1.00 | Reference | 1.00 | Reference | ||
| 50-70 | 1.06 | (0.82-1.37) | .648 | 1.41 | (1.21-1.65) | <.001 |
| rDRI | ||||||
| Low | 1.00 | Reference | 1.00 | Reference | ||
| Intermediate | 1.18 | (0.91-1.55) | .218 | 1.46 | (1.06-2.02) | .022 |
| High or very high | 1.89 | (1.34-2.66) | <.001 | 2.35 | (1.71-3.23) | <.001 |
| Conditioning | ||||||
| TBI-RIC | 1.00 | Reference | 1.00 | Reference | ||
| TBI-MAC | 0.97 | (0.61-1.55) | .909 | 0.94 | (0.77-1.14) | .514 |
| Non–TBI-RIC | 1.84 | (1.33-2.53) | <.001 | 1.74 | (1.43-2.12) | <.001 |
| Non–TBI-MAC | 1.73 | (1.14-2.61) | .010 | 1.36 | (1.02-1.82) | .037 |
| GVHD prophylaxis | ||||||
| CI + MMF | 1.00 | Reference | 1.00 | Reference | ||
| CI + MTX | NA | NA | NA | 1.47 | (1.22-1.79) | <.001 |
| CI + steroid | 0.86 | (0.56-1.31) | .496 | NA | NA | NA |
| Others | 1.19 | (0.84-1.69) | .318 | 1.70 | (1.38-2.10) | <.001 |
| TNCs at collection per recipient weight (×107/kg)† | ||||||
| -First quartile | 1.00 | Reference | 1.00 | Reference | ||
| First-second quartile | 0.67 | (0.47-0.96) | .028 | 0.93 | (0.75-1.14) | .465 |
| Second-third quartile | 0.84 | (0.59-1.18) | .314 | 0.91 | (0.74-1.12) | .358 |
| Third quartile - | 0.88 | (0.61-1.26) | .482 | 0.98 | (0.80-1.21) | .874 |
| Number of HLA-MM | ||||||
| 0-1 | 1.00 | Reference | 1.00 | Reference | ||
| 2- | 1.36 | (1.03-1.81) | .030 | 1.17 | (0.96-1.42) | .119 |
95% CI, 95% confidence interval; HLA-MM, HLA mismatches; NA, not available.
Results of the analysis statistically significant (with P < .05) are highlighted in bold.
Indicates patients' age at CBT.
TNCs at collection per recipient weight (×107/kg) was categorized into 4 groups using the quartiles as referred in the Table 1.